US Sees Increasing Diversity In Generic Formulations
While Next Five Years Could Be ‘Coming-Out Party’ For US Biosimilars
Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.
